[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530984":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":43,"centralContacts":48,"locations":53,"responsibleParty":250,"collaborators":31,"id":252,"slug":253,"hasResults":254,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":31,"eligibilityCriteria":258,"healthyVolunteers":254,"sex":259,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":31,"studyType":265,"phases":266,"briefSummary":269,"conditions":270,"keywords":273,"overallStatus":56,"whyStopped":31,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":292},{"fullName":5,"class":6},"Kyverna Therapeutics","INDUSTRY",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"KYV-101 CAR-T cells with lymphodepletion conditioning","EXPERIMENTAL","Phase 2: Dosing with KYV-101 CAR-T cells",[13,14],"Drug: Standard lymphodepletion regimen","Biological: KYV-101",{"label":16,"type":10,"description":17,"interventionNames":18},"KYV-101 Treatment","Phase 3",[13,14],{"label":20,"type":21,"description":22,"interventionNames":23},"Standard of Care","ACTIVE_COMPARATOR","Phase 3 Optional crossover to receive KYV-101 Treatment after 24 weeks",[24,13,14],"Drug: Standard of Care Treatment",[26,32,38],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Standard of Care Treatment","Standard of Care Medications Optional Crossover to receive KYV-101 treatment",[20],null,{"type":27,"name":33,"description":33,"armGroupLabels":34,"otherNames":35},"Standard lymphodepletion regimen",[9,16,20],[36,37],"Cyclophosphamide","Fludarabine",{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":31},"BIOLOGICAL","KYV-101","Anti-CD19 CAR-T cell therapy",[9,16,20],[44],{"name":45,"affiliation":46,"role":47},"MD","Kyverna Therapeutics, Inc.","STUDY_DIRECTOR",[49],{"name":46,"role":50,"phone":51,"phoneExt":31,"email":52},"CONTACT","510-925-2484","Clinicaltrials@kyvernatx.com",[54,71,82,94,106,118,130,142,154,166,178,190,200,210,220,230,240],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"University of California, Irvine","RECRUITING","Orange","California","92868","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-117.85311,33.78779,{"lat":66,"lon":65},[69],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},"Study Coordinator",{"facility":72,"status":56,"city":73,"state":58,"zip":74,"country":60,"countryCode":61,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Stanford University Medical Center","Palo Alto","94305",{"type":63,"coordinates":76},[77,78],-122.14302,37.44188,{"lat":78,"lon":77},[81],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":83,"status":56,"city":84,"state":85,"zip":86,"country":60,"countryCode":61,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"University of Miami","Miami","Florida","33149",{"type":63,"coordinates":88},[89,90],-80.19366,25.77427,{"lat":90,"lon":89},[93],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":95,"status":56,"city":96,"state":97,"zip":98,"country":60,"countryCode":61,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Indiana University Health","Indianapolis","Indiana","46202",{"type":63,"coordinates":100},[101,102],-86.15804,39.76838,{"lat":102,"lon":101},[105],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":107,"status":56,"city":108,"state":109,"zip":110,"country":60,"countryCode":61,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"University of Missouri","Columbia","Missouri","65212",{"type":63,"coordinates":112},[113,114],-92.33407,38.95171,{"lat":114,"lon":113},[117],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":119,"status":56,"city":120,"state":121,"zip":122,"country":60,"countryCode":61,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Thomas Jefferson University Hospital","Philadelphia","Pennsylvania","19107",{"type":63,"coordinates":124},[125,126],-75.16362,39.95238,{"lat":126,"lon":125},[129],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":131,"status":56,"city":132,"state":133,"zip":134,"country":60,"countryCode":61,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Houston Methodist Hospital","Houston","Texas","77030",{"type":63,"coordinates":136},[137,138],-95.36327,29.76328,{"lat":138,"lon":137},[141],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":143,"status":56,"city":144,"state":145,"zip":146,"country":60,"countryCode":61,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Intermountain Medical Center","Murray","Utah","84107",{"type":63,"coordinates":148},[149,150],-111.88799,40.66689,{"lat":150,"lon":149},[153],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":155,"status":56,"city":156,"state":31,"zip":31,"country":157,"countryCode":158,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Westmead Institute for Medical Research","Westmead","Australia","AU",{"type":63,"coordinates":160},[161,162],150.98768,-33.80383,{"lat":162,"lon":161},[165],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":167,"status":56,"city":168,"state":31,"zip":31,"country":169,"countryCode":170,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Hospital Israelita Albert Einstein","São Paulo","Brazil","BR",{"type":63,"coordinates":172},[173,174],-46.63611,-23.5475,{"lat":174,"lon":173},[177],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":179,"status":56,"city":180,"state":31,"zip":31,"country":181,"countryCode":182,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"Charite- Universitätsklinikum Berlin","Berlin","Germany","DE",{"type":63,"coordinates":184},[185,186],13.41053,52.52437,{"lat":186,"lon":185},[189],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":191,"status":56,"city":192,"state":31,"zip":31,"country":181,"countryCode":182,"cosmosGeoPoint":193,"geoPoint":197,"contacts":198},"Universitätsklinikum der Ruhr-Universität Bochum","Bochum",{"type":63,"coordinates":194},[195,196],7.21648,51.48165,{"lat":196,"lon":195},[199],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":201,"status":56,"city":202,"state":31,"zip":31,"country":181,"countryCode":182,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"Universitätsklinikum Hamburg-Eppendorf","Hamburg",{"type":63,"coordinates":204},[205,206],9.99302,53.55073,{"lat":206,"lon":205},[209],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":211,"status":56,"city":212,"state":31,"zip":31,"country":181,"countryCode":182,"cosmosGeoPoint":213,"geoPoint":217,"contacts":218},"Medizinische Hochscule Hannover","Hanover",{"type":63,"coordinates":214},[215,216],9.73322,52.37052,{"lat":216,"lon":215},[219],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":221,"status":56,"city":222,"state":31,"zip":31,"country":181,"countryCode":182,"cosmosGeoPoint":223,"geoPoint":227,"contacts":228},"Friedrich-Schiller-Universität Jena","Jena",{"type":63,"coordinates":224},[225,226],11.5899,50.92878,{"lat":226,"lon":225},[229],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":231,"status":56,"city":232,"state":31,"zip":31,"country":181,"countryCode":182,"cosmosGeoPoint":233,"geoPoint":237,"contacts":238},"Universitätsklinik Magdeburg","Magdeburg",{"type":63,"coordinates":234},[235,236],11.63189,52.13129,{"lat":236,"lon":235},[239],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"facility":241,"status":56,"city":242,"state":31,"zip":31,"country":181,"countryCode":182,"cosmosGeoPoint":243,"geoPoint":247,"contacts":248},"Technical University Munich, Klinikum Rechts der Isar","Munich",{"type":63,"coordinates":244},[245,246],11.57549,48.13743,{"lat":246,"lon":245},[249],{"name":70,"role":50,"phone":31,"phoneExt":31,"email":31},{"type":251,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100530984","phase-2-kysa-6-a-study-of-anti-cd19-chimeric-antigen-receptor-t-cell-therapy-in-patients-with-generalized-myasthenia-gravis-100530984",false,"NCT06193889","KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis","KYSA-6: A Phase 2\u002F3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis","Key Inclusion Criteria\n\n1. Presence of autoantibodies to AChR or MuSK\n2. Myasthenia Gravis Foundation of America (MGFA) Class II-IV\n3. MG-Activities of Daily Living (MG-ADL) total score of ≥6 at screening and confirmed at baseline visit\n4. QMG total score of ≥11 at screening an confirmed at baseline visit\n5. Failed treatment with 2 or more immunosuppressive\u002Fimmunomodulatory therapies, or failed at least 1 immunosuppressive therapy and required chronic plasmapheresis, or IVIG (or subcutaneous or intramuscular Ig) to control symptoms\n6. On a stable dose of glucocorticoids and\u002For other immunotherapies for ≥1 month prior to screening. For patients treated with azathioprine, a stable dose for ≥2 months prior to screening is required\n7. No change in dose of acetylcholinesterase inhibitors for ≥2 weeks prior to screening\n8. No use of intravenous immune globulin (IVIG) or plasmapheresis (PLEX) within 4 weeks of screening or pre-dose baseline (unless this is part of their SOC treatment regimen)\n9. No use of rituximab (or any other anti-CD20 or CD19 monoclonal antibody) within 12 weeks prior to screening\n10. Able and willing to attend the necessary visits to the study site\n\nKey Exclusion Criteria\n\n1. Unable to washout or interrupt autoimmune disease therapy prior to apheresis and\u002For baseline if required\n2. Co-occurring neurological autoimmune disease (ie, Lambert-Eaton Myasthenic Syndrome) or any disease affecting the neuromuscular junction or muscle causing weakness (eg, myositis, myopathy, motor neuropathy)\n3. History of stroke (with residual sequalae and\u002For risk for recurrence), seizure (even if well controlled on antiepileptics), neurodegenerative disease, altered mental status (unexplained and\u002For recent\u002Fcurrent), or uncontrolled\u002Fsevere psychiatric disease\n4. Any serious and\u002For uncontrolled medical condition that, in the investigator's judgment, would cause unacceptable safety risk, interfere with study procedures or results, or compromise compliance with the protocol, including but not limited to, clinically significant cardiac or pulmonary disease\n5. History of primary immunodeficiency, organ or allogeneic bone marrow transplant, or splenectomy\n6. Active, uncontrolled, viral, bacterial, or systemic fungal infection or recent history of repeated infections\n7. Thymectomy \\\u003C12 months of screening or planned during the study\n8. Prior treatment with gene therapy product or cellular immunotherapy (eg, CAR T) requiring vector integration and directed at any target\n9. Patients requiring chronic anticoagulation therapy that cannot be discontinued for medical procedures","ALL","18 Years","75 Years",{"count":263,"type":264},66,"ESTIMATED","INTERVENTIONAL",[267,268],"PHASE2","PHASE3","A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis",[271,272],"Myasthenia Gravis","Generalized Myasthenia Gravis",[40,274,275,276,277,278,279,280,281,282],"myasthenia gravis","autoimmune disease","anti-CD19 CAR-T Therapy","cellular therapy","MG","KYSA-6","KYV101-006","mivocabtagene autoleucel","miv-cel","2026-05-13",{"date":285,"type":286},"2026-05-15","ACTUAL",{"date":288,"type":286},"2024-08-28",{"date":290,"type":264},"2028-09",{"name":5,"class":6},17]